Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Trial ID or NCT#

NCT02247804

Status

recruiting iconRECRUITING

Purpose

This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Official Title

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. -Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.
Exclusion Criteria:
  1. - Previous enrollment in another Allergan Bimatoprost SR Study. - Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye - Anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration - History of glaucoma surgery

Investigator(s)

Ann Caroline Fisher, MD
Ann Caroline Fisher, MD
Glaucoma specialist, Cataract specialist
Clinical Associate Professor, Ophthalmology

Contact us to find out if this trial is right for you.

Contact

Kristina Liu
(408) 726-5119